Bedrijfsoverzicht
BioAtla, Inc. is a clinical-stage biopharmaceutical enterprise focused on developing specific and selective antibody-based therapeutics designed for the treatment of solid tumor cancer. The company operates within the healthcare sector, specifically inside the biotechnology industry, which implies a high-risk, high-reward environment characterized by significant research and development expenditures before potential commercialization. BioAtla, Inc. maintains a relatively small operational scale with a market capitalization of $7.39 million, annual revenue of $2.00 million, and an employee count of 41. These valuation and revenue figures indicate that the company is currently in an early-stage development phase, where limited revenue generation is typical as resources are allocated primarily toward advancing product candidates like mecbotamab vedotin through clinical trials rather than large-scale commercial sales.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $2.00 million against a net income of $-59,607,000, while the EBITDA stood at $-58,332,000. The substantial gap between the modest revenue of $2.00 million and the significant net loss reveals a cost structure dominated by heavy operational and research expenses that far exceed current income generation. Free cash flow for the period was $-22,801,624, which indicates that the company is consuming cash reserves to fund its development activities rather than generating liquidity from operations. Regarding profitability metrics, the gross margin is recorded at 0.0%, the operating margin is -462.8%, and the profit margin is 0.0%. The negative operating margin exceeding 100% in magnitude suggests that operating expenses have surpassed total revenue, a common characteristic in biotechnology firms before reaching commercial milestones. On the balance sheet, the company holds $7.12 million in cash while carrying $6.20 million in debt, though the debt-to-equity ratio is listed as N/A due to the equity structure. Despite holding more cash than debt, the negative financial position is reflected in a return on assets of -110.8%, which indicates that the asset base is currently generating losses rather than returns. Liquidity is constrained as evidenced by a current ratio of 0.37, signaling that current assets are insufficient to cover current liabilities without external financing or asset sales. Return on equity is also N/A, further highlighting the challenges in measuring efficiency in a loss-making entity.
Waarderingsbeoordeling
The valuation metrics present a complex picture with a trailing P/E ratio of N/A and a forward P/E of -3.34. The existence of a negative forward P/E implies that the market expects earnings to remain negative or that the current valuation model relies on non-GAAP adjustments, as traditional earnings-based multiples are not applicable to a company with no net income. The price-to-book ratio is -7.37, which indicates a market valuation that is negative relative to book value, often seen in biotech firms where intangible assets and R&D are not fully captured on the balance sheet. Alternative valuation measures show a price-to-sales ratio of 3.69 and an EV/EBITDA of -0.11, suggesting the market is pricing the company based on its revenue potential and pipeline prospects rather than current profitability or earnings power. The stock has experienced significant volatility, trading between a 52-week high of $71.50 and a 52-week low of $3.92. While the specific current price is not explicitly provided in the source data to calculate a precise percentage, the range demonstrates the extreme price discovery process typical of small-cap biotechnology stocks. The beta value is 1.21, which means the stock price is expected to be 21% more volatile than the broader market index. This elevated beta reflects the heightened sensitivity of the stock to market movements and the specific risks associated with the clinical-stage nature of the business.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A. The absence of year-over-year growth data reflects the early stage of the company's commercial operations, where historical comparison is not yet meaningful for assessing growth trajectories. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%. This absence of dividend distribution is consistent with the company's strategy of reinvesting all available earnings, including any future profits, back into the development of its therapeutic candidates rather than distributing cash to shareholders. Consequently, the company's growth and income profile is defined entirely by its ability to advance its clinical pipeline and eventually generate commercial revenue, as there is no current income component or dividend history to analyze.